Champalimaud Foundation

Lisbon 1400-038

2 studies enrolling now · 11 studies all time

What they study most

Breast Cancer, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chronic Lymphoproliferative Diseases (CLPD), Lymphoma, Mantle-Cell, Myelodysplastic Syndromes, Neoplasm Metastasis, Plasma Cell Disorder, Relapsed or Refractory Multiple Myeloma

Studies at this site

• A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) — Recruiting now
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now
• Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) — Running, not enrolling
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer — Running, not enrolling
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer — Running, not enrolling
• The OPBC-07/microNAC Study — Running, not enrolling
• Safety of Pregnancy in BRCA Mutated Breast Cancer Patients — Completed
• BD OneFlow CLPD Panel (BD OneFlow LST, and B-CLPD T1 to T4 Assays) on the BD FACSLyric System. — Completed
• Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) — Stopped early
• Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer — Completed
• Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer — Completed